A small retrospective study of women receiving taxane therapy for breast or ovarian cancer while pregnancy showed no statistically significant outcomes in maternal or fetal health.
Read the abstract here
Related Topics
FDA Gives Its First-Ever Approval of Treatment for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with … Continued
OCRA’s Early Career Investigator Grant Recipients
Ovarian Cancer Research Alliance is proud to support five outstanding scientists through our Early Career Investigator Grants, part of the $6 million in new research OCRA is funding in 2025. These … Continued
OCRA’s Collaborative Research Development Grant & Microsoft AI for Health Grantees
OCRA is proud to announce the first three recipients of the $6 million we have awarded to support groundbreaking ovarian and related gynecologic cancer research in 2025. And we’re not … Continued